Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

Mirum and Incyte announced that the U.S. FDA approved Atebrioz (zilurgisertib) for adult and pediatric patients with fibrodysplasia ossificans progressiva. The approval creates a new commercial opportunity in a rare-disease indication and is a significant regulatory milestone for both companies.